Quality of care measurement for patients with ovarian cancer in Japan

Abstract

AbstractAimQuality of care is important to reduce disease progression, and improve both survival and quality of life. The Japan Society of Gynecologic Oncology has published treatment guidelines to promote standardized high‐quality care for ovarian cancer in Japan. We developed quality indicators based on the guideline recommendations and used them on large datasets of health service use to examine the quality of ovarian cancer care.MethodsA panel of experts developed the indicators using a modified Delphi method. Adherence to each indicator was evaluated using data from a hospital‐based cancer registry of patients diagnosed in 2018. All patients receiving first‐line treatment at participating facilities were included. The adherence rates were returned to participating hospitals, and reasons for nonadherence were collected. A total of 580 hospitals participated, and the study examined the care received by 6611 patients with ovarian cancer and 1879 with borderline tumors using 11 measurable quality indicators.ResultsThe adherence rate ranged from 22.6% for “Estrogen replacement within 6 months of operation” to 93.5% for “Bleomycin, etoposide, and cisplatin for germ cell tumor more than Stage II.” Of 580 hospitals, 184 submitted the reasons for nonadherence.ConclusionsThe quality of ovarian cancer care should be continuously assessed to encourage the use of best practices. These indicators may be a useful tool for this purpose.